Gain-of-function somatic cell lines for drug discovery applications generated by homologous recombination.

Assay and drug development technologies

Volumn 1, Issue 6, 2003, Pages 755-765

  Zeh, Karin ^a   Sanders, Pamela ^a   Londo, Phillip ^a   Crute, James J ^a   Pollok, Brian A ^a   Whitney, Michael A ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; CELL RECEPTOR; DRUG DERIVATIVE; MC4R PROTEIN, HUMAN; MELANOCORTIN 4 RECEPTOR; MSH, 4 NLE 7 PHE ALPHA; MSH, 4-NLE-7-PHE-ALPHA-; TRANSCRIPTION FACTOR;

ARTICLE; CELL LINE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; GENE TARGETING; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; HUMAN; HYBRID CELL; METHODOLOGY; PHARMACEUTICS; PHYSIOLOGY;

ALPHA-MSH; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE TARGETING; GENETIC VECTORS; HUMANS; HYBRID CELLS; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINATION, GENETIC; TECHNOLOGY, PHARMACEUTICAL; TRANSCRIPTION FACTORS;

EID: 7944230148     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/154065803772613390     Document Type: Article

References (0)